Accepted Manuscript

Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trials

Fabrizio Manetti

PII: S0223-5234(18)30507-5

DOI: 10.1016/j.ejmech.2018.06.016

Reference: EJMECH 10486

To appear in: European Journal of Medicinal Chemistry

Received Date: 27 March 2018


Revised Date: 5 June 2018

Accepted Date: 6 June 2018

Please cite this article as: F. Manetti, Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trials, *European Journal of Medicinal Chemistry* (2018), doi: 10.1016/j.ejmech.2018.06.016.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.





LIMK + cofilin + AMP-PNP (5hvk) \longrightarrow LIMK + pSer3-cofilin + hydrolyzed AMP-PNP

Download English Version:

https://daneshyari.com/en/article/7796040

Download Persian Version:

https://daneshyari.com/article/7796040

Daneshyari.com